Evaluating the protective effect of 1.0% sodium-Hyaluronate, used during capsulorhexis and IOL implantation in phacoemulsification surgery, on corneal endothelial cells

A Clinical Comparison of Safety and Efficacy in Phacoemulsification with versus without Ophthalmic Viscoelastic Device. A Randomized Clinical Study.

Article specifications

This clinical trial was published in 2015 in informa healthcare journal (IF 2015:0.87) by Turkish ophthalmologist. The aim of the study was to evaluate the protective effect of 1.0% sodium-Hyaluronate, used during capsulorhexis and IOL implantation in phacoemulsification surgery, on corneal endothelial cells. The study was on 21 patients diagnosed with senil cataract, divided in two groups Phacoemulsification was performed using 1.0% sodium-Hyaluronate, which is commonly used as one of the ophthalmic viscoelastic devices in Group V and without OVDs in Group H.

Results

The result does not indicate that the use of OVDs during phacoemulsification has no direct protective effect on CEC (Corneal Endothelial Cell), but indicates that many other factors that cause CEC loss during phacoemulsification might be more important. It is beyond dispute that 1.0% sodium-Hyaluronate used during phacoemulsification facilitates the procedure, makes it safer, and provides substantial benefits during the training period.